Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.57 USD
Change Today -0.01 / -0.39%
Volume 24.4K
As of 11:34 AM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

100 Cumming Center

Suite 151-B

Beverly, MA 01915

United States

Phone: 978-236-8717

Fax: 978-921-6564

Cellceutix Corporation, a clinical stage biotechnology company, focuses on discovering small molecule drugs for hard to treat diseases, including drug-resistant cancers, psoriasis, autism and inflammatory disease. Products Brilacidin; The intravenous formulation of Brilacidin has the potential to treat various indications, including Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by either drug-sensitive or drug-resistant strains of Staphylococcus aureus bacteria. The company has completed enrollment of 215 patients in a Phase 2b clinical trial for ABSSSI. Kevetrin: The company’s main cancer compound, Kevetrin, is in its ninth cohort in a Phase 1 clinical trial at Harvard Cancer Center's Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center, testing Kevetrin against advanced solid tumors. The company has conducted pre-clinical studies in lung cancer, head and neck cancer, colon cancer, breast cancer, prostate cancer, pancreatic cancer and in leukemia models. Prurisol: In 2012, the company participated in a pre investigational new drug application meeting with the U.S. Food and Drug Administration (FDA) pertaining to Prurisol its compound targeting psoriasis. Delparantag: Delparantag is a synthetic, small-molecule intended to reverse the effects of the commonly used anticoagulants unfractionated heparin (UFH), and its derivatives, low molecular weight heparins (LMWH), to help manage the balance of antithrombosis and anticoagulation and reduce the incidence of bleeding in certain interventional cardiology procedures, such as Percutaneous Coronary Intervention (PCI) and Coronary Arterial Bypass Grafting (CABG), and other situations where UFH and LMWH are used and bleeding may occur. The company is evaluating this drug for other diseases, including Chronic Obstructive Pulmonary Disease (COPD). Strategy The company’s strategy is to use its business and scientific expertise to maximize the value of diverse pipeline. Regulations The Federal Food, Drug and Cosmetic Act, and other federal and state statutes and regulations, govern the testing, manufacture, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion of the company’s products. Intellectual Property The company has trademark protection for the marks PolyMedix, PolyCide, and PolyDentix. The company has been assigned all right title and interest to the following eight pharmaceutical compounds: Kevetrin; KM 277; KM 278; Prurisol; KM 362; KM 3174; KM 732; and KM-391. Significant Events In September 2013, the company purchased substantially all of the assets of Polymedix Inc, and Polymedix Pharmaceuticals, Inc. from the U.S. Bankruptcy Court. PolyMedix Inc. was founded based on technology licensed from the University of Pennsylvania. History Cellceutix Corporation was founded in 2007.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTIX:US $2.57 USD -0.01

CTIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CTIX.
View Industry Companies
 

Industry Analysis

CTIX

Industry Average

Valuation CTIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 31.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLCEUTIX CORP, please visit www.cellceutix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.